Country/Region: Baltic (Latvia, Lithuania, Estonia)
PE Guidelines

Baltic guideline for economic evaluation of pharmaceuticals (Pharmacoeconomic Analysis)(2002)
PDF in English

PE Guidelines Source:
Additional Information:
Information up to date as of Wednesday, January 17, 2018

PE Guidelines Key Features:

Key Features:  
Title and year of the document
Baltic guideline for economic evaluation of pharmaceuticals (Pharmacoeconomic Analysis)(2002) 
Affiliation of authors
Experts from health authorities of the Baltic countries 
Purpose of the document
Drug reimbursement and other state funding decisions 
Standard reporting format included
No 
Disclosure
Yes 
Target audience of funding/ author's interests
Pharmaceutical companies. Baltic states’ health authority 
Perspective
Mainly health care perspective. If relevant, societal 
Indication
Approved one(s) 
Target population
Yes 
Subgroup analysis
Yes 
Choice of comparator
Most commonly used alternative or practice. Be justified. 
Time horizon
To model a sufficient analysis period when trial data provide too short a time frame 
Assumptions required
Not stated 
Preferred analytical technique
Any one of CMA, CEA, CUA. Need justification. 
Costs to be included
Only direct health care costs. If relevant, include all costs outside healthcare system, presented separately. 
Source of costs
Adapt local cost. Be specified. 
Modeling
Yes, requires details 
Systematic review of evidences
Encourage meta-analysis 
Preference for effectiveness over efficacy
Prefer data from RCTs 
Preferred outcome measure
Change in the health state. Absolute risk difference calculated 
Preferred method to derive utility
EuroQol, Health Utility Index 
Equity issues stated
Not stated 
Discounting costs
Yes, 5% justify for other rates 
Discounting outcomes
Yes, 5% 
Sensitivity analysis-parameters and range
Main assumption variables, confidence interval 
Sensitivity analysis-methods
Details of the statistical tests performed 
Presenting results
C/E ratio, ICER, total annual cost and benefit 
Incremental analysis
Yes 
Total costs vs effectiveness (cost/effectiveness ratio)
Yes 
Portability of results (Generalizability)
Adjustment needed 
Financial impact analysis
No 
Mandatory or recommended or voluntary
 

Acknowledgement: Eglė Urbonavičiūtė, Chief specialist, deputizing for the Head of Medical Technology Division, State Health Care Accreditation Agency (VASPVT), Vilnius, Lithuania and Diāna Arāja, Head, Pharmacy Division, Ministry of Health of the Republic of Latvia, Riga, Latvia

Country Selection Page | PE Guidelines Index Page